Tyrosine kinase inhibitors: Why does the current process of clinical development not apply to them?

Carlos L. Arteaga, Jose Baselga

Research output: Contribution to journalComment/debate

85 Scopus citations

Abstract

The robust clinical activity of imatinib and trastuzumab for treatment of chronic myeloid leukemia, gastrointestinal stromal tumors, and breast cancer has demonstrated that blocking pathogenic tyrosine kinases can alter the natural history of human tumors. On the other hand, EGF receptor inhibitors have shown overall modest activity. The contrast in the development of these agents implies that both molecular target dependence and patient selection are essential for the successful outcome of this process. We will contrast lessons derived from the development of inhibitors of Abl, c-Kit, HER2/neu (erbB2), and EGFR, highlight successes and limitations in the field, and propose new approaches for clinical development of tyrosine kinase inhibitor therapy.

Original languageEnglish (US)
Pages (from-to)525-531
Number of pages7
JournalCancer Cell
Volume5
Issue number6
DOIs
StatePublished - Jun 2004

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Fingerprint Dive into the research topics of 'Tyrosine kinase inhibitors: Why does the current process of clinical development not apply to them?'. Together they form a unique fingerprint.

  • Cite this